50
Participants
Start Date
May 21, 2021
Primary Completion Date
December 30, 2024
Study Completion Date
December 30, 2024
Selinexor (80mg/d)
"Selinexor (ATG-010) is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.~Arm I:80mg/d QW ;"
Selinexor (100mg/d)
"Selinexor (ATG-010) is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.~Arm II:100mg/d QW ;"
Pegylated liposomal doxorubicin
25 mg/m\^2 intravenously on day 1 , QW
Dexamethasone
Dexamethasone 40mg/d QW
Cyclophosphamide
Cyclophosphamide:300mg/m2, d1 QW,
RECRUITING
Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan
NOT_YET_RECRUITING
Zhongnan Hospital of Wuhan University, Wuhan
RECRUITING
Henan Cancer Hospital, Zhengzhou
NOT_YET_RECRUITING
The First Affiliated Hospital of Air Force Medical University, Xi’an
NOT_YET_RECRUITING
The Second Affiliated Hospital of Xi'an Jiaotong University, Xi’an
Chunyan Sun, MD
OTHER